SCM
MDGL icon

Sterling Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sterling Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
289
+76
+36% +$38.9K ﹤0.01% 1282
2026
Q1 		$111K Buy
213
+91
+75% +$43.5K ﹤0.01% 1362
2025
Q4 		$71K Buy
122
+77
+171% +$39.3K ﹤0.01% 1661
2025
Q3 		$20.6K Buy
45
+4
+10% +$1.49K ﹤0.01% 2121
2025
Q2 		$12.4K Buy
41
+22
+116% +$6.55K ﹤0.01% 1993
2025
Q1 		$6.29K Buy
19
+1
+6% +$329 ﹤0.01% 2042
2024
Q4 		$5.55K Hold
18
– – ﹤0.01% 2432
2024
Q3 		$3.82K Buy
+18
New +$4.61K ﹤0.01% 1867

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's MDGL Position: Q2 2026 in Review

Sterling Capital Management increased its Madrigal Pharmaceuticals (MDGL) stake by 36% in Q2 2026, buying an estimated $38.9K and bringing the position to 289 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #1282.

Sterling Capital Management first reported a position in MDGL in Q3 2024 and has held it in 8 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Sterling Capital Management held 289 shares of Madrigal Pharmaceuticals worth $155K as of Q2 2026.
  • Sterling Capital Management bought 76 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $38.9K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1282 holding.
  • Sterling Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.